Across the globe, healthcare providers are embracing new GLP-1 medications to combat the obesity crisis, which now affects over 1 billion people worldwide. However, leading health authorities have issued a clear and consistent warning - medication alone is not enough. (1)
The World Health Organization (WHO) now recommends that GLP-1 therapies be combined with intensive behavioural support, including structured counselling (2). The Journal of the American Medical Association (JAMA) reinforces this with a call for comprehensive, person-centered care, essential for positive long term outcomes (3). In the UK, NICE guidelines mandate that these prescriptions are accompanied by four pillars of support, including psychological care.
This has created a significant service delivery gap. Health systems are prescribing these new medications without the properly trained staff to provide the essential psychological and behavioral support required for safe and effective use. This oversight not only fails to meet clinical best practice but also risks poor patient outcomes, high attrition rates, and non-compliance with national and international health standards.
References
[1] NCD Risk Factor Collaboration (NCD-RisC). (2024). Worldwide trends in underweight and obesity from 1990 to 2022. The Lancet, 403(10431), 1027-1050.
[2] World Health Organization. (2025, December 1). WHO issues global guideline on the use of GLP-1 medicines in treating obesity.
[3] Celletti, F., Farrar, J., & De Regil, L. (2025). World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. Published online December 01, 2025.